Drug Regulatory Authority of Pakistan

  • Home
  • Drug Regulatory Authority of Pakistan

Drug Regulatory Authority of Pakistan Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Drug Regulatory Authority of Pakistan, Government Organization, 2nd Floor, Block C, .

21/09/2015

MINISTRY OF NATIONAL HEALTH SERVICES,
REGULATIONS & COORDINATION
DRUG REGULATORY AUTHORITY OF PAKISTAN (DRAP)




PRE-QUALIFICATION FOR FURNISHING/FURNITURE WORKS

The Drug Regulatory Authority of Pakistan (DRAP), Ministry of National Health Services, Regulations & Coordination (employer) invites reputable Firms for Pre-qualification for the works of DRAP Head Office Furnishing/Furniture Works at TF Complex project, G-9/4, Islamabad. The site has a covered area of 30,000 Sq.ft comprising of four floors consisting of Low/full height, meeting and conference rooms. It is a fast track project requiring furnishing/furniture on an urgent basis.

Only registered suppliers, who are on Active Taxpayers List (ATL) of FBR, are eligible to supply goods / services to Government departments as per FBR letter C.No.3 (2) ST&FE/LP&E/Misc/2014/121940-R dated 3rd September, 2015

Appropriate registered Furniture Manufacturing/Supplying Firms registered with relevant authorities having a minimum experience for Pre-qualification requirement of successfully completing furnishing/supplying furniture for Office building project.

The Prequalification documents are available on written request for a non refundable fee of Rs 1000/- in shape of pay order/call deposit in favor of CITE’ Architecture/Planning & Design Group CITE Design Group 7 9 I &T Center, G-8/1, Islamabad Phone No. 051-2289264 & 051-2335519. The documents will be available from 22-09-2015 onwards till 29-09-2015. The documents can also be downloaded from DRAP website (www.dra.gov.pk) free of cost.

Completed Pre-qualification documents may be delivered in sealed envelopes by hand or through registered mail, to:- Director Administration (DRAP), Room No. 235, C Block, Pak Secretariat, Islamabad not later than: October 06-10-2015 till 12.00 pm. Proposal will be opened on the same day at 02.00 pm.

DRAP reserves the right to reject any or all applications as per PPRA rules.

This advertisement is also available at DRAP website and PPRA website.



(Dr. Raja Mustafa Hyder)
Director (Admn, HR & Log)
Drug Regulatory Authority of Pakistan,
Room 235, C-Block, Pak Secretariat, Islamabad.
Tel: 051-9203003

03/08/2015

NOTICE FOR MEETING OF THE APPELLATE BOARD

It is hereby notified that the 143rd meeting of the Appellate Board is scheduled to be held on 29th July, 2015 at 10.30 a.m in the committee room, first floor, Ministry of National Health Services, Regulations and Coordination, G-5/2, Islamabad. Below mentioned appeals will be considered by the Appellate Board. Although letters have already been issued to the individual Appellants through UMS, for attending the subject meeting, however, through this notice, below mentioned Appellants are once again informed :-

i. To appear before the Appellate Board in person or through a duly authorized representative who is well versant with the matter to make further submission, if any, in support of your Appeals as you may deem fit.
ii. Please note that if you or your representative fails to appear before the Board on the date fixed, the case will proceed and ex-parte decision may be taken.
iii. No TA/DA will be admissible.
iv. Kindly acknowledge the receipt of this letter and confirm your attendance along with a letter of authorization / nomination for the person(s) appearing on your behalf.


a) Fresh Appeals:-

Sr. No. Appeal No. Name of the Appellant Brief of Appeal
1. 19/2013 M/s Festel Laboratories, Lahore. Appeal against the cancellation of registration of Dudofen Tablet 40 mg (Famotidine) Reg. No. 034611 by the Registration Board in its 237th Meeting held on 26-02-2013.

2. 03/2014 M/s Sanofi-Aventis Pakistan Limited, Karachi Appeal against decision of Registration Board taken in its 242nd meeting wherein the Board did not accede to the request of the appellant for transfer of registration of Thymoglobulin (Reg. No. 069513) from M/s Scitech Health (Pvt) Ltd., Karachi to M/s Sanofi-Aventis.

3. 04/2014 M/s Ghazi Brothers, Karachi Appeal against the order dated 12th June, 2014 passed in the 243rd meeting of the Registration Board regarding rejection of registration application of Analgin Solution for Injection.

4. 05/2014 M/s Servier Research and Pharmaceuticals [Pakistan](Pvt) Ltd., Lahore Appeal against decision of Registration Board taken in its 245th meeting wherein the Board rejected the registration application due to reason that Daflon 1gm is not approved by any reference regulatory authority i.e., US FDA, EMA, TGA, MHRA and in country of origin i.e., France and that safety and efficacy data has not been provided.
5. 01/2015 M/s ICI Pakistan Limited, Karachi Appeal against decision of Registration Board communicated vide letter No. F. 3-4/2014 Reg-I (M-245) dated 6th November, 2014.
6. 02/2015 M/s Biocare Pharmaceutica, Lahore. Appeal against decision of Registration Board communicated vide letter No. F. 3-4/2014 Reg-I (M-245) dated 10th November, 2014 rejecting registration application of Ceflet 0.75g for injection.
7. 03/2015 M/s Biocare Pharmaceutica, Lahore. Appeal against decision of Registration Board communicated vide letter No. F. 3-4/2014 Reg-I (M-245) dated 10th November, 2014 rejecting registration application of Ceflet 1.5g for injection.
8. 04/2015 M/s Biocare Pharmaceutica, Lahore. Appeal against decision of Registration Board communicated vide letter No. F. 3-4/2014 Reg-I (M-245) dated 10th November, 2014 rejecting registration application of Ceflet 3.0g for injection.
9. 05/2015 M/s Biocare Pharmaceutica, Lahore. Appeal against decision of Registration Board communicated vide letter No. F. 3-4/2014 Reg-I (M-245) dated 10th November, 2014 rejecting registration application of Xtra 1.5g for injection.
10. 06/2015 M/s Biocare Pharmaceutica, Lahore. Appeal against decision of Registration Board communicated vide letter No. F. 3-4/2014 Reg-I (M-245) dated 10th November, 2014 rejecting registration application of Xtra 3.0g for injection.
11. 07/2015 M/s Weather Folds Pharmaceuticals, Hattar. Appeal against decision of Central Licensing Board taken in its 238th meeting communicated vide letter No. F. 3-6/2007-Lic (Vol-I) dated 5th December, 2014.

b) Appeals deferred in the previous meetings of the Board: -
Sr. No. Appeal No. Name of the Appellant Brief of Appeal
1. 1987 M/s. Novo Nordisk Pharma, Khi Appeal against the decision of Drug Pricing Committee for fixation of low MRP of Mixtard 30 ® FlexPen 100IU Reg. No. 069522.
2. 1988 M/s. Novo Nordisk Pharma, Khi Appeal against the decision of Drug Pricing Committee for fixation of low MRP of Insulatard ® FlexPen 100IU Reg. No. 069524.
3. 1989 M/s. Novo Nordisk Pharma, Khi Appeal against the decision of Drug Pricing Committee for fixation of low MRP of Actrapid ® FlexPen 100IU Reg. No. 069523.
4. 1997 M/s. ISIS Pharmaceuticals and Chemical Works, Karachi Appeal against the decision of Registration Board regarding cancellation of registration of Stop-P 50mg (Diclofenac Potassium) Tablets, Registration No. 028140.

5. 20/2013 M/s Wyeth Pakistan Limited, Karachi. Appeal against the cancellation of registration of Myambutol INH Forte (Reg. No. 031293) by the Registration Board in its 237th Meeting held on 26-02-2013.

c) Miscellaneous Case(s): -

Sr. No. Appeal No. Name of the Appellant Brief of Appeal
1. 01/2013 M/s Efroze Chemical Industries (pvt.) Ltd., Karachi Appeal against orders passed by Central Licensing Board on 30-01-2013.

Corrigendume for Job Advertisement
30/04/2015

Corrigendume for Job Advertisement

Job Advertisement
30/04/2015

Job Advertisement

30/04/2015

TO BE PUBLISHED IN PART-I OF THE NEXT ISSUE OF
THE WEEKLY GAZETTE OF PAKISTAN

Government of Pakistan
Ministry of National Health Services, Regulations & Coordination
Drug Regulatory Authority of Pakistan
“C” Block, Pak Secretariat, Islamabad
*********

Islamabad, the 27th April, 2015

NOTIFICATION

No.F.2-26/2014-Admn-I In exercise of the powers conferred under Section 36 of the Drug Regulatory Authority of Pakistan Act, 2012 (Act No.XXI of 2012) and in accordance with Section 15 (5) (a) & (b) and DRAP Notification No.F.11-28/2012-DDC (I&E) dated
11th December 2012, the Federal Government is pleased to offer one time irrevocable option to all DRAP Employees either to continue in the present pay and service structure as a Civil Servant or to opt for absorption in the Authority within a period of thirty (30) days from the date of issuance of this Notification.

(Dr. Mohammad Aslam)
Chief Executive Officer

The Manager,
Printing Corporation of Pakistan Press,
Karachi.

Copy to:

1. Federal Government.
2. Law, Justice & Human Rights Division.
3. Finance Division.
4. PS to Secretary, M/o NHSR&C
5. APS to JS (Admin), M/o NHSR&C
6. SO (Admn-I / DRAP), M/o NHSR&C
7. Director (Admn, HR & Log), DRAP.
8. O.O. Register.

Chief Executive Officer

Medical Devices Rules, 2015 Approved and Notified on 09-03-2015 (85-119 pages)
15/03/2015

Medical Devices Rules, 2015 Approved and Notified on 09-03-2015 (85-119 pages)

Medical Devices Rules, 2015 Approved and Notified on 09-03-2015 (43-84 pages)
15/03/2015

Medical Devices Rules, 2015 Approved and Notified on 09-03-2015 (43-84 pages)

Medical Devices Rules, 2015 Approved and Notified on 09-03-2015 (1-42 pages)
15/03/2015

Medical Devices Rules, 2015 Approved and Notified on 09-03-2015 (1-42 pages)

Drug Pricing Policy, 2015
14/03/2015

Drug Pricing Policy, 2015

Notification (Priority of Pending Registration Applications)
14/03/2015

Notification (Priority of Pending Registration Applications)

Final Annual Procurement
19/02/2015

Final Annual Procurement

Evaluation Report As Per Rule 35 of PP Rules
10/11/2014

Evaluation Report As Per Rule 35 of PP Rules

Address

2nd Floor, Block C

44000

Telephone

+92519202566

Alerts

Be the first to know and let us send you an email when Drug Regulatory Authority of Pakistan posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Organization

Send a message to Drug Regulatory Authority of Pakistan:

Shortcuts

  • Want your organization to be the top-listed Government Service?

Share